tapentadol (CG5503)

DRUG2 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions

ArthralgiaBunionHallux ValgusOsteoarthritis, KneePain

Phase 3

Tapentadol (CG5503)

CompletedNCT00421928

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Osteoarthritis, Knee, Pain

Start: 2007-01-31End: 2008-12-31Updated: 2012-04-18

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

CompletedNCT00613938

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Arthralgia, Bunion, Hallux Valgus +1

Start: 2008-02-29End: 2008-10-31Updated: 2014-05-09

Related Papers

Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.

2015-10-0134 citations

Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.

2015-09-0124 citations

Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis.

2014-08-0113 citations

A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.

2013-09-015 citations

Efficacy of tapentadol ER for managing moderate to severe chronic pain.

2013-01-0141 citations